Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Use of whole genome sequencing in surveillance of drug resistant tuberculosis.

McNerney R, Zignol M, Clark TG.

Expert Rev Anti Infect Ther. 2018 May;16(5):433-442. doi: 10.1080/14787210.2018.1472577. Epub 2018 May 9.

PMID:
29718745
2.

Priorities for global political momentum to end TB: a critical point in time.

Kasaeva T, Baddeley A, Floyd K, Jaramillo E, Lienhardt C, Nishikiori N, Weil DE, Weyer K, Zignol M.

BMJ Glob Health. 2018 Mar 23;3(2):e000830. doi: 10.1136/bmjgh-2018-000830. eCollection 2018. No abstract available.

3.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

4.

Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey.

Pavlenko E, Barbova A, Hovhannesyan A, Tsenilova Z, Slavuckij A, Shcherbak-Verlan B, Zhurilo A, Vitek E, Skenders G, Sela I, Cabibbe AM, Cirillo DM, de Colombani P, Dara M, Dean A, Zignol M, Dadu A.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):197-205. doi: 10.5588/ijtld.17.0254.

PMID:
29506617
5.

Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.

Lim DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, Cabibbe AM, Zignol M, Basilio RP, Garfin AMC, Ama MCG.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702571. doi: 10.1183/13993003.02571-2017. Print 2018 Mar. No abstract available. Erratum in: Eur Respir J. 2018 May 30;51(5):.

PMID:
29496754
6.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

7.

Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey.

Tagliani E, Hassan MO, Waberi Y, De Filippo MR, Falzon D, Dean A, Zignol M, Supply P, Abdoulkader MA, Hassangue H, Cirillo DM.

Sci Rep. 2017 Dec 15;7(1):17672. doi: 10.1038/s41598-017-17705-3.

8.

Epidemiology of Drug-Resistant Tuberculosis.

Dean AS, Cox H, Zignol M.

Adv Exp Med Biol. 2017;1019:209-220. doi: 10.1007/978-3-319-64371-7_11. Review.

PMID:
29116637
9.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

PMID:
29097434
10.

Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones - Authors' reply.

Zignol M, Floyd K.

Lancet Infect Dis. 2017 Jan;17(1):25. doi: 10.1016/S1473-3099(16)30538-2. No abstract available.

PMID:
27998569
11.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

12.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

13.

Sputum smear microscopy result: a predictor for drug-resistant tuberculosis?

Dean AS, Zignol M, Lumb R, Lalor M, Skrahina A, Floyd K.

Int J Tuberc Lung Dis. 2016 Jul;20(7):864-5. doi: 10.5588/ijtld.15.0977.

PMID:
27287635
14.

Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya.

Jezmir J, Cohen T, Zignol M, Nyakan E, Hedt-Gauthier BL, Gardner A, Kamle L, Injera W, Carter EJ.

PLoS One. 2016 May 11;11(5):e0154142. doi: 10.1371/journal.pone.0154142. eCollection 2016.

15.

The Burden of Drug-Resistant Tuberculosis in Papua New Guinea: Results of a Large Population-Based Survey.

Aia P, Kal M, Lavu E, John LN, Johnson K, Coulter C, Ershova J, Tosas O, Zignol M, Ahmadova S, Islam T.

PLoS One. 2016 Mar 22;11(3):e0149806. doi: 10.1371/journal.pone.0149806. eCollection 2016.

16.

Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan.

Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, Zignol M.

Int J Tuberc Lung Dis. 2016 Apr;20(4):448-55. doi: 10.5588/ijtld.15.0645.

PMID:
26970152
17.

Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.

Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, Gallarda J, Hanna D, Kim PS, Liwski R, Miotto P, Schito M, Zignol M.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S141-6. doi: 10.1093/cid/civ610.

18.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

19.

National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned.

Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K.

Trop Med Int Health. 2015 Sep;20(9):1128-1145. doi: 10.1111/tmi.12534. Epub 2015 Jun 7.

20.

Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S39-49. doi: 10.1093/infdis/jiu682. Review.

21.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

22.

On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data.

Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):105-23. doi: 10.1016/j.drup.2014.10.001. Epub 2014 Oct 6.

23.

Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M.

Eur Respir J. 2015 Jan;45(1):150-60. doi: 10.1183/09031936.00101814. Epub 2014 Sep 26.

24.

Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.

Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, Hoffmann H, Hoffner S, Floyd K.

Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28. Review.

25.

Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider.

Marais BJ, Tadolini M, Zignol M, Migliori GB.

Eur Respir J. 2014 Mar;43(3):678-84. doi: 10.1183/09031936.00133613. No abstract available.

26.

HIV and multidrug-resistant tuberculosis: overlapping epidemics.

Dean AS, Zignol M, Falzon D, Getahun H, Floyd K.

Eur Respir J. 2014 Jul;44(1):251-4. doi: 10.1183/09031936.00205413. Epub 2014 Feb 13. No abstract available.

27.

Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.

Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, van Gemert W, Hoffmann H, Zignol M, Kremer K, Gombogaram T, Gadoev J, du Cros P, Muslimova N, Jalolov A, Dadu A, de Colombani P, Telnov O, Slizkiy A, Kholikulov B, Dara M, Falzon D.

Euro Surveill. 2013 Oct 17;18(42). pii: 20609.

28.

Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data.

Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC.

Lancet Infect Dis. 2013 Aug;13(8):690-7. doi: 10.1016/S1473-3099(13)70130-0. Epub 2013 Jun 4.

PMID:
23743044
29.

Multidrug-resistant tuberculosis, Somalia, 2010-2011.

Sindani I, Fitzpatrick C, Falzon D, Suleiman B, Arube P, Adam I, Baghdadi S, Bassili A, Zignol M.

Emerg Infect Dis. 2013 Mar;19(3):478-80. doi: 10.3201/eid1903.121287. Erratum in: Emerg Infect Dis. 2014 Nov;20(11):1961.

30.

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M.

Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Review.

31.

Drug-resistant tuberculosis: time for visionary political leadership.

Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Jun;13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6. Epub 2013 Mar 24. Review.

32.

Multidrug resistance in new tuberculosis patients: burden and implications.

Royce S, Falzon D, van Weezenbeek C, Dara M, Hyder K, Hopewell P, Richardson MD, Zignol M.

Int J Tuberc Lung Dis. 2013 Apr;17(4):511-3. doi: 10.5588/ijtld.12.0286.

PMID:
23485384
33.

Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Al-Hajoj S, Varghese B, Shoukri MM, Al-Omari R, Al-Herbwai M, Alrabiah F, Alrajhi AA, Abuljadayel N, Al-Thawadi S, Zumla A, Zignol M, Raviglione MC, Memish Z.

Antimicrob Agents Chemother. 2013 May;57(5):2161-6. doi: 10.1128/AAC.02403-12. Epub 2013 Mar 4.

34.

Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors.

Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, Rusovich V, Dadu A, de Colombani P, Dara M, van Gemert W, Zignol M.

Bull World Health Organ. 2013 Jan 1;91(1):36-45. doi: 10.2471/BLT.12.104588. Epub 2012 Nov 26.

35.

Multidrug-resistant tuberculosis in children: evidence from global surveillance.

Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K.

Eur Respir J. 2013 Sep;42(3):701-7. doi: 10.1183/09031936.00175812. Epub 2012 Dec 6.

36.

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, Gilpin C, de Dieu Iragena J, Falzon D, Raviglione M.

Eur Respir J. 2013 Jul;42(1):252-71. doi: 10.1183/09031936.00157212. Epub 2012 Nov 22. Review.

37.

Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43. doi: 10.5588/ijtld.11.0811.

PMID:
23107633
38.

Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country.

Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M, Cohen T.

Eur Respir J. 2013 Nov;42(5):1291-301. doi: 10.1183/09031936.00111812. Epub 2012 Oct 25.

39.

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP.

Tuberculosis (Edinb). 2012 Sep;92(5):397-403. doi: 10.1016/j.tube.2012.06.003. Epub 2012 Jul 10.

40.

Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010.

Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M.

Bull World Health Organ. 2012 Feb 1;90(2):111-119D. doi: 10.2471/BLT.11.092585. Epub 2011 Nov 7.

41.

Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.

PMID:
22283887
42.

Multidrug resistance among new tuberculosis cases: detecting local variation through lot quality-assurance sampling.

Hedt BL, van Leth F, Zignol M, Cobelens F, van Gemert W, Nhung NV, Lyepshina S, Egwaga S, Cohen T.

Epidemiology. 2012 Mar;23(2):293-300. doi: 10.1097/EDE.0b013e3182459455.

43.

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.

PMID:
22008772
44.

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V, Zignol M.

Eur Respir J. 2012 Jun;39(6):1425-31. doi: 10.1183/09031936.00145411. Epub 2011 Oct 17.

45.

Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.

Jenkins HE, Zignol M, Cohen T.

PLoS One. 2011;6(7):e22927. doi: 10.1371/journal.pone.0022927. Epub 2011 Jul 29.

46.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

47.

Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey.

Samo Gudo P, Cuna Z, Coelho E, Maungate S, Borroni E, Miotto P, Ahmadova S, Brouwer M, Migliori GB, Zignol M, Cirillo DM.

Eur Respir J. 2011 Jul;38(1):222-4. doi: 10.1183/09031936.00182010. No abstract available.

48.

Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys.

Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D, Zignol M, van Leth F, Egwaga SM, Van Deun A.

Int J Tuberc Lung Dis. 2011 Jul;15(7):959-65. doi: 10.5588/ijtld.10.0515.

PMID:
21682972
49.

Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing.

Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M.

Clin Infect Dis. 2011 Apr 1;52(7):901-6. doi: 10.1093/cid/cir081.

50.

Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories.

Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL.

Int J Tuberc Lung Dis. 2011 Jan;15(1):116-24.

PMID:
21276307

Supplemental Content

Loading ...
Support Center